Global Management of Infectious Disease After Ebola

, by ; ;
Global Management of Infectious Disease After Ebola by Halabi, Sam F.; Gostin, Lawrence O.; Crowley, Jeffrey S., 9780190604882
Note: Supplemental materials are not guaranteed with Rental or Used book purchases.
  • ISBN: 9780190604882 | 0190604883
  • Cover: Hardcover
  • Copyright: 10/26/2016

Purchase Options
  • Rent

    (Recommended)

    $86.52
    Term
    Due
    Price
    *This item is part of an exclusive publisher rental program and requires an additional convenience fee. This fee will be reflected in the shopping bag.
  • Buy New

    Usually Ships in 3-5 Business Days

    $110.77
  • eBook

    eTextBook from VitalSource Icon

    Available Instantly

    Online: 180 Days

    Downloadable: 180 Days

    *To support the delivery of the digital material to you, a digital delivery fee of $3.99 will be charged on each digital item.
    $48.99*
The 2014-2015 Ebola outbreak in West Africa shocked the world with its devastation and its rapid migration to multiple continents. As the systems meant to respond to this sort of epidemic failed, the disease exposed not just weaknesses in international infectious disease surveillance and management, but the failures of governments, humanitarian organizations, and international institutions to handle the legal, ethical, and economic questions that arose with an event of this scale.

Global Management of Infectious Disease After Ebola unites the insights of Ebola's first responders with those the world's foremost experts in law, economics, vaccine development, and global migration to identify missed opportunities from the Ebola crisis -- and to apply these lessons to emerging infectious disease threats. Framed with critical discussions of both the global health financing infrastructures that precipitated the response and the ethical and human rights dilemmas that resulted from it, this volume is much more than postmortem to an outbreak: it is a vital, sometimes damning examination of where we've been and where we're going in the face of emerging infectious diseases.